Výsledky vyhledávání - "Nozar Azarnia"

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Autor: Aref Al-Kali, Afoluso Ronnee Adesanya, Erica D. Warlick, Wiesław Wiktor Jędrzejczak, Anna Jonasova, Guillermo Garcia-Manero, Matthew Parris, Richard C. Woodman, Selina M. Luger, Nozar Azarnia, María Díez-Campelo, David Valcárcel

Publikováno v: Blood. 134:4249-4249

Background: Patients with HR-MDS have a dismal prognosis after failure of hypomethylating agents (HMAs) (Zeidan 2014), with median overall survival (OS) of less than 6 months (Prebet 2011) and currently no approved second-line therapy (Garcia-Manero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8193b900e2d00a6b9027b8def6230698
https://doi.org/10.1182/blood-2019-132127

Zobrazit plný text záznamu

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Autor: Nadia Amellal, Roger Ove, Hagop Youssoufian, Roger B. Cohen, Nozar Azarnia, David Raben, Christopher U. Jones, Jordi Giralt, Jacek Jassem, Ranjan Sur, K. Kian Ang, Eric K. Rowinsky, Paul M. Harari, James A. Bonner, Dong M. Shin, José Baselga, Merrill S. Kies

Publikováno v: New England Journal of Medicine. 354:567-578

BACKGROUND We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a3027b3cd59c5e0af5ebcc25acbbf7
https://doi.org/10.1056/nejmoa053422

Zobrazit plný text záznamu

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Autor: Shireen Vali, Michael E. Petrone, Steven M. Fruchtman, Nozar Azarnia, Hannes Loferer, Himanshu Grover, Shahabuddin Usmani, Neeraj Kumar Singh, Taher Abbasi, Lewis R. Silverman, Guillermo Garcia-Manero, Bernard H. Brownstein

Publikováno v: Blood. 128:4324-4324

Background: MDS is a marrow stem cell disorder with limited treatments. Due to outcome heterogeneity of MDS, it is imperative to identify prognostic tools for patients in clinical trials. Rigosertib (RIG) is a RAS-mimetic that inhibits cellular signa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc0a7114731c1f989d69a1f8d19f8078
https://doi.org/10.1182/blood.v128.22.4324.4324

Zobrazit plný text záznamu

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Autor: Courtney D. DiNardo, Nozar Azarnia, Shyamala C. Navada, Naveen Pemmaraju, Katherine P. Hearn, Lewis R. Silverman, Naval Daver, Erin P. Demakos, Yesid Alvarado, Marina Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia, Pierre Fenaux, Steve Fruchtman, Gautam Borthakur, Rosalie Odchimar-Reissig

Publikováno v: Blood. 126:910-910

[Graphic][1] Background: Rigosertib (RIG) is a Ras-mimetic that inhibits the PI3K and PLK cellular signaling pathways by binding directly to the Ras-binding Domain found in Ras effector proteins. It has been tested as a single agent in patients (pts)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da1e6e31d5c377a781a0c1a1cec01a51
https://doi.org/10.1182/blood.v126.23.910.910

Zobrazit plný text záznamu

Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Autor: Steven Best, Guillermo Garcia-Manero, Steve Fructman, Nozar Azarnia, Lewis R. Silverman, Michael E. Petrone, Ghulam J. Mufti

Publikováno v: Blood. 126:5257-5257

Background: The aging marrow stem cell demonstrates more somatic mutations when compared to younger marrow stem cells. These abnormalities have been noted in pts with MDS, as well as in patients with normal peripheral blood counts (Steensma et al, Bl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::783626dbb048fb41be4bada82b1b168d
https://doi.org/10.1182/blood.v126.23.5257.5257

Zobrazit plný text záznamu

Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome

Autor: Valeria Santini, Peter L. Greenberg, John F. Seymour, Nozar Azarnia, Shyamala Chendal Navada, Guillermo Garcia-Manero, Michael E. Petrone, Pierre Fenaux, Lewis R. Silverman, Barbara R Snyder, Erin P Demakos

Publikováno v: Journal of Clinical Oncology. 33:7017-7017

7017 Background: BMBL % is the prognostic variable with the greatest impact on outcome in MDS patients at diagnosis and subsequent time points. Current composite response criteria (IWG, Cheson 2006...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed53a50b4011c8b64b4cc1e6b9ed6fae
https://doi.org/10.1200/jco.2015.33.15_suppl.7017

Zobrazit plný text záznamu

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

Autor: Shirin Khambata-Ford, Heinz-Josef Lenz, Philip Stella, Eric K. Rowinsky, Nozar Azarnia, Robert J. Mayer, Allen Lee Cohn, Eric Van Cutsem, David J. Mauro, Andrew William Pippas, B. Mirtsching, Zenta Tsuchihashi, Philip J. Gold

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(30)

Purpose This multicenter study evaluated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in metastatic colorectal carcinoma (CRC) refractory to irinotecan, oxaliplatin, and a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76d19055690bdd3116db315b3ddde693
https://pubmed.ncbi.nlm.nih.gov/17050875

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání